Literature DB >> 12974043

[Development and initial validation of an instrument to measure the lifestyles of type 2 diabetes mellitus patients 2].

Juan Manuel López-Carmona1, Cuauhtémoc Raúl Ariza-Andraca, José Raymundo Rodríguez-Moctezuma, Catarina Munguía-Miranda.   

Abstract

OBJECTIVE: To develop and validate a specific instrument to measure lifestyle of type 2 diabetes mellitus (DM2) patients.
MATERIAL AND METHODS: A longitudinal, observational, prospective study was conducted between March 2001 and April 2002 at family medicine healthcare units of the Instituto Mexicano del Seguro Social (Mexican Institute of Social Security (MISS)) in Mexico State's East District. A self-administered instrument (instrument to measure diabetic lifestyles, IMEVID) was designed to measure the lifestyles of diabetic patients. It was submitted for review by a multidisciplinary group of experts who assessed its logical and content validity to measure the lifestyle in DM2 patients. The instrument was administered on two different days to 412 adult subjects with DM2. Some items were excluded on the basis of the frequency with which their answer choices were selected, as well as the item-total correlation, and the item's significant loads in several domains in factorial analysis.
RESULTS: The sample population consisted of 389 (94.7% response) subjects who completed the study. Intraclass correlation coefficients for logical and content validity were 0.91 and 0.95 respectively. After depuration of items, the instrument had 25 closed items grouped in 7 domains: nutrition, physical activity, tobacco consumption, alcohol consumption, information on diabetes, emotions, and therapeutic adherence. The global rating of the questionnaire had a Cronbach's alpha of 0.81 and a test-retest correlation coefficient of 0.84.
CONCLUSIONS: The specific questionnaire IMEVID is the first to measure the lifestyle in subjects with DM2. It has logical validity, content validity, and a good level of consistency.

Entities:  

Mesh:

Year:  2003        PMID: 12974043

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  6 in total

1.  Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico.

Authors:  María Cecilia Anzaldo-Campos; Sonia Contreras; Adriana Vargas-Ojeda; Rufino Menchaca-Díaz; Addie Fortmann; Athena Philis-Tsimikas
Journal:  Diabetes Technol Ther       Date:  2016-02-25       Impact factor: 6.118

2.  [Design and validation of a questionnaire to assess the level of general knowledge on eating disorders in students of Health Sciences].

Authors:  Violeida Sánchez Socarrás; Alicia Aguilar Martínez; Cristina Vaqué Crusellas; Raimon Milá Villarroel; Fabián González Rivas
Journal:  Aten Primaria       Date:  2015-12-24       Impact factor: 1.137

Review 3.  Patient-reported outcomes for diabetes and hypertension care in low- and middle-income countries: A scoping review.

Authors:  Sarah Masyuko; Carrie J Ngongo; Carole Smith; Rachel Nugent
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

4.  The Validity and Reliability of the FANTASTIC Questionnaire for Nutritional and Lifestyle Studies in University Students.

Authors:  María Teresa Murillo-Llorente; Renata Brito-Gallego; María Luisa Alcalá-Dávalos; María Ester Legidos-García; Javier Pérez-Murillo; Marcelino Perez-Bermejo
Journal:  Nutrients       Date:  2022-08-14       Impact factor: 6.706

5.  Comparison of primary health-care models in the management of chronic kidney disease.

Authors:  Alfonso M Cueto-Manzano; Héctor R Martínez-Ramírez; Laura Cortés-Sanabria
Journal:  Kidney Int Suppl (2011)       Date:  2013-05

6.  Do People with Type 2 Diabetes Think They are Unhealthy?: A Cross-Sectional Study in Celaya, Mexico.

Authors:  Karla C Paz-Salinas; Nicolas Padilla-Raygoza; Silvia C Delgado-Sandoval; Georgina Olvera-Villanueva; Ma Laura Ruiz-Paloalto
Journal:  Cent Asian J Glob Health       Date:  2015-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.